TABLE 2.

Susceptibility testing of UPC2 disruption strainsa

DrugDrug targetMIC (μg/ml)Fold changeb
BWP17S-7D-6EC-7EC-2
FluconazoleErg11p210.191.5211
ItraconazoleErg11p0.0160.0080.0020.0320.0168
KetoconazoleErg11p0.0160.0080.0020.0160.0128
TerbinafineErg1p10010.12510012.5800
FenpropimorphErg2p6.36.30.256.2512.525
LovastatinHmg1p16161161616
Nikkomycin ZChitin synthetase1253.93.912512532
Calcofluor whiteChitin deposition6415.63.16412821
Amphotericin BErgosterol0.190.190.190.250.191
CycloheximideLSU rRNA2502502502502501
DTTReducing agent0.511111
SDSPlasma membrane0.0250.0250.0130.0250.0252
  • a All strains were grown in RPMI 1640 medium supplemented with arginine, histidine, and uridine for 48 h. Data reflect the MIC80 cutoff. MICs for itraconazole and amphotericin B were determined by Etest. Other MICs were determined by the standard NCCLS microdilution protocol.

  • b Fold change = WT/D6 (homozygous deletion strain).